Melinta Therapeutics (Melinta Therapeutics) Total Current Assets : $131.27 Mil (As of Sep. 2019)

View and export this data going back to 2012. Start your Free Trial

What is Melinta Therapeutics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Melinta Therapeutics's total current assets for the quarter that ended in Sep. 2019 was $131.27 Mil.

Melinta Therapeutics Total Current Assets Historical Data

The historical data trend for Melinta Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melinta Therapeutics Total Current Assets Chart

Melinta Therapeutics Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Total Current Assets

Get a 7-Day Free Trial

104.85

161.98

15.09

149.76

149.48

Melinta Therapeutics Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Total Current Assets	Get a 7-Day Free Trial															165.07	149.48	181.76	156.76	131.27

Melinta Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Melinta Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2018 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	81.808	+	22.485	+	41.341	+	3.848
	=	149.48

Melinta Therapeutics's Total Current Assets for the quarter that ended in Sep. 2019 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	63.521	+	18.933	+	39.275	+	9.538
	=	131.27

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Melinta Therapeutics (OTCPK:MLNTQ) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Melinta Therapeutics's Liquidation Value for the quarter that ended in Sep. 2019 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	63.521	-	289.022	+	0.75 * 18.465	+	0.5 * 39.275
=	-192.01

Melinta Therapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Melinta Therapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Melinta Therapeutics (Melinta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Melinta Therapeutics Inc (OTCPK:MLNTQ) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

44 Whippany Road, Morristown, NJ, USA, 07963

Website

http://www.melinta.com

Melinta Therapeutics Inc is a clinical-stage biotechnology company that develops differentiated antibiotics for acute care and community settings. The company's goal is to develop treatments for bacterial infectious diseases, particularly respiratory tract infections and staphylococcal infections. The company is particularly focused on treating community-acquired bacterial pneumonia, as well as gonorrhea and other indications.

Executives

John Johnson	director, officer: Chief Executive Officer	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Thomas P Koestler	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David Zaccardelli	director	300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Bruce Downey	director
Garheng Kong	director	712 COLLEGE AVENUE, MENLO PARK CA 94025
Daniel Mark Wechsler	director, officer: See Remarks	2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8
John Temperato	officer: Chief Commercial Officer	C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Goldstein Dov A Md	director
Michael R Dougherty	director	C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
P Sherrill Neff	director	C/O RESOURCE AMERICA, INC., 1845 WALNUT STREET, 18TH FLOOR, PHILADELPHIA PA 19103
Prabhavathi Fernandes	director, officer: President and CEO	114 MILTON AVENUE, CHAPEL HILL NC 27514
Intersouth Partners Vii L P	10 percent owner	406 BLACKWELL SUITE 200, DURHAM NC 27701
Intersouth Associates Vii, Llc	10 percent owner	406 BLACKWELL STREET, SUITE 200, DURHAM NC 27701
Intersouth Associates Vi, Llc	10 percent owner	406 BLACKWELL STREET, SUITE 200, DURHAM NC 27701